TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least~1 psoriatic skin lesion. Exclusion Criteria:~• -Subject has known history of active tuberculosis.~* Subject has a planned surgical intervention between baseline and the week 52 evaluation.~* Subject has an active infection or history of infections.~* Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, diabetes, anemia) considered by the Investigator to be clinically significant and uncontrolled.~* Subject has any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.~Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)~• Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 210 mg brodalumab (Type: EXPERIMENTAL): Administered via subcutaneous injections.
- 140 mg brodalumab (Type: EXPERIMENTAL): Administered via subcutaneous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Administered via subcutaneous injection until week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 80 to 120 days inclusive on the day of inclusion.~* Born at full term of pregnancy (\> 37 weeks)~* Informed consent form signed by the parent(s) or other legal representative according to local regulations~* Parent(s) or legal representative able to attend all scheduled visits and to understand and comply with the study procedures (able to read and write; access to a telephone).~Exclusion Criteria:~* Rectal temperature ≥ 38.0°C~* Moderate or severe acute illness with or without fever~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination~* Having received any DTaP, IPV, or Hib vaccines prior to study initiation or any vaccination in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known history of diphtheria, tetanus, pertussis, H. influenzae type b infections, poliomyelitis~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Systemic hypersensitivity to any of the vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde)~* History of a life-threatening reaction (such as encephalopathy, Hypotonic Hyporesponsive Episode, severe fever, convulsions, etc.) to the trial vaccine or a vaccine containing the same substances~* Blood or blood-derived products (immunoglobulins) received in the past 4 weeks~* Vaccination planned in the 6 weeks following any trial vaccination~* Known HIV seropositivity~* Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination~* History of seizures or progressive, evolving or unstable neurological condition~* Clinically significant findings on review of systems that might interfere with correct vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the vaccine or pose a health risk to the subject.

- Gender: ALL
- Minimum Age: 80 Days
- Maximum Age: 120 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Participants will receive PEDIACEL vaccine
- Group 2 (Type: ACTIVE_COMPARATOR): Participants will receive Infanrix-IPV+Hib vaccines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Application of Vitamin E on Anal Fissure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of chronic anal fissure~Exclusion Criteria:~* patients with associated anal pathologies~* intestinal inflammation disorders~* immunosuppression~* fissures secondary to underlying diseases (eg, AIDS, tuberculosis, or sexually transmitted diseases)~* patients with a history of headaches, heart disease, or intolerance to nitrates~* pregnant or lactating women~* patients with closed angle glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin E acetate (Type: EXPERIMENTAL): Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
- Glyceryl trinitrate ointment (Type: ACTIVE_COMPARATOR): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide Low Threshold in Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory Epilepsy, males~Exclusion Criteria:~* Females, peripheric neuropathy

- Gender: MALE
- Minimum Age: 17 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: EXPERIMENTAL): Open-labeled preliminary trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levosimendan Versus Dobutamine for Renal Function in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written, signed and dated informed consent~* Male and Female subjects ≥18 years of age~* Chronic congestive heart failure scheduled for right sided cardiac catheterization~* Left ventricular ejection fraction ≤ 40% determined by echocardiography~* Elevation of N Terminal-proBNP ≥ 500 ng/L~* Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)~Exclusion Criteria:~* Acute heart failure, untreated~* Systolic blood pressure \< 80 mmHg~* Tachycardia above 100 bpm~* Angina Canadian Cardiovascular Society (CCS) class III or higher~* Aortic stenosis~* Hypertrophic cardiomyopathy~* Restrictive cardiomyopathy~* The presence of kidney disease diagnosed before heart failure~* Administration of radiographic contrast \< 1 week~* Radiographic contrast allergy~* In the Investigator's opinion, the patient has a clinically significant disease that could be adversely affected by study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levosimendan (Type: ACTIVE_COMPARATOR): Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
- Dobutamine (Type: ACTIVE_COMPARATOR): Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients allergic to grasses pollen~* patients with bronchial asthma~* patients with controlled asthma~* patients who were qualified for immunotherapy and gave written informed consent for immunotherapy~Exclusion Criteria:~* patients allergic for other perennial and seasonal allergens~* patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients completed the core study BAF312A2201~* Written informed consent provided before any assessment of the extension study~* Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception~Exclusion Criteria:~* Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)~* Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions~* Active infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 56 Years
- Healthy Volunteers: f

Study Arms:
- BAF312 10 mg/2 mg (Type: EXPERIMENTAL): 10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 2 mg/2 mg (Type: EXPERIMENTAL): 2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 1.25 mg/2 mg (Type: EXPERIMENTAL): 1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 .5 mg/2 mg (Type: EXPERIMENTAL): .5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
- BAF312 .25 mg/2 mg (Type: EXPERIMENTAL): .25 mg dose in Double Blind Phase and 2 mg in Open Label Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 20-40 years;~* American Standards Association status I-II.~Exclusion Criteria:~* Patients with allergy or hypersensitivity to propofol, lipid emulsion, or granisetron;~* History of nausea or vomiting within 24h before cesarean delivery;~* History of gastrointestinal or psychiatric disease, motion sickness, smoking, postoperative nausea and vomiting;~* Morbid obesity;~* Consumption of drugs such as opioids, antiemetics , H2 antagonists, phenothiazines and/or corticosteroids within 24h before the study period;~* Any chronic medical or surgical disorders complicating the pregnancy;~* Conditions contraindicating regional anesthesia.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- propofol group (Type: EXPERIMENTAL): first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
- control group (Type: PLACEBO_COMPARATOR): first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin DPPIV Inhibitor add-on Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes~* Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these~* Patients will be screened by a blood test and only those who need additional therapy can be enrolled~Exclusion Criteria:~* Patients with type 1 diabetes~* Patients with very poorly controlled diabetes~* Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Dapagliflozin 10 mg tablet
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 years or older to less than 65 years, inclusive (at time of informed consent)~* Subjects with a current diagnosis of schizophrenia, as defined by DSM-IV-TR criteria and a history of the illness for at least three years prior to screening (as per subject, family, healthcare provider, or by previous medical records).~* Subjects with a stable living environment, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s).~* Subjects who showed previous response to antipsychotic treatment in the past year.~* Subjects who are currently treated with oral or depot antipsychotics other than clozapine or who have had a recent lapse in antipsychotic treatment requiring chronic treatment with antipsychotic medication for stabilization.~* Subjects who are experiencing a current acute exacerbation of psychotic symptoms requiring stabilization~* Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.~Exclusion Criteria:~* Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product~* Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator~* Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current DSM-IV-TR Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)~* Subjects experiencing acute depressive symptoms within the past 30 days~* Subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history~* Subjects with a significant risk of violent behavior; who represent a risk of committing suicide~* Subjects with clinically significant tardive dyskinesia~* Subjects currently treated with insulin for diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator for 52 weeks
- Brexpiprazole (OPC-34712) (Type: EXPERIMENTAL): Brexpiprazole (OPC-34712) for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* undergo chemotherapy for any one of the following settings:~  1. Setting 1: Neoadjuvant chemotherapy prior to cheom-RT~ 2. Setting 2: Palliative chemotherapy in Chemonaive patients~ 3. Setting 3: Palliative chemotherapy in previously treated patients (i.e. 2nd line or 3rd line chemo)~* Age \>= 18 years~* (ECOG) performance status of 0-2~* have detectable levels of pEBV DNA at baseline~* have measurable tumor sites by RECIST criteria~* have adequate bone marrow, renal and hepatic functions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- advanced nasopharyngeal carcinoma (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiographic Progression of Infiltrated Caries Lesions In-vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14-35 year old subjects~* decayed-missing-filled permanent teeth (DMFT) ≥ 3~* having at least two early caries lesions in approximal posterior tooth surfaces~* lesion visible on radiograph~Exclusion Criteria:~* Current participation in another clinical study~* Medically compromised subjects~* Hyposalivation~* Pregnancy~* Allergic to methylmethacrylates~* Allergic to latex~* Symptomatic teeth

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Preventative measures (Type: PLACEBO_COMPARATOR): Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
- Lesion infiltration (Type: ACTIVE_COMPARATOR): Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of DSP-5423P in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria~* Patients who are aged 18 years or older at informed consent~* Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.~Exclusion Criteria:~* Patients who fall under a contraindication listed in the LONASEN® package insert~* Patients with Parkinson disease, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DSP-5423P (Type: EXPERIMENTAL): Percutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients aged 18-70 years of age~* Documented obstructive sleep apnea by polysomnography (AHI 5 or more/hr)~* Established diagnosis of PTSD related to any past lifetime traumatic event and have a diagnosis of current, chronic PTSD~Exclusion Criteria:~* Central sleep apnea defined as central apnea/hypopnea \>50% of the total respiratory events~* Prior treatment for sleep apnea~* Veterans with fewer than 4 teeth remaining in either arch~* Coexisting narcolepsy~* Tempo-mandibular joint disease~* Epilepsy~* Prominent suicidal or homicidal ideation~* Diagnosis of dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CPAP First, MAD (Type: ACTIVE_COMPARATOR): CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks
- MAD First, CPAP (Type: EXPERIMENTAL): MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete